Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major atherosclerotic cardiovascular disease markets reached a value of US$ 23.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 29.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.15% during 2024-2034.

The atherosclerotic cardiovascular disease market has been comprehensively analyzed in IMARC's new report titled "Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Atherosclerotic cardiovascular disease (ASCVD) is a prevalent medical condition characterized by the progressive buildup of plaque within the arteries, leading to reduced blood flow and potential blockages. This ailment primarily occurs in the coronary arteries, causing health complications, such as heart attacks and strokes. The symptoms of the disorder can vary depending on the affected regions and the extent of plaque buildup. Some common indications include chest pain (angina), shortness of breath, fatigue, weakness, etc. In a few cases, the disease may remain asymptomatic until a significant blockage occurs, leading to a sudden and severe event like a heart attack. The diagnosis of ASCVD involves a comprehensive evaluation of a patient's medical history, risk factors, and physical examination. The healthcare provider may often utilize various diagnostic tests and procedures, such as cholesterol and lipid level assessments, stress tests, electrocardiograms (ECGs), and imaging techniques like angiography or coronary CT scans, to confirm the diagnosis.

The escalating prevalence of plaque formation, which can cause hardening and narrowing of the arteries, resulting in reduced blood flow, is primarily driving the atherosclerotic cardiovascular disease market. In addition to this, the inflating utilization of effective medications, including statins, cholesterol absorption inhibitors, antiplatelet agents, etc., for managing the symptoms of the condition and preventing further damage is creating a positive outlook for the market. Moreover, the widespread implementation of lifestyle modifications, such as adopting healthy diets, regular exercise, and smoking cessation, to reduce cholesterol levels, promote weight loss, and improve cardiovascular health, is also propelling the market growth. Apart from this, the increasing utilization of minimally invasive procedures, like angioplasty and stent placement, that can unclog blocked arteries and restore blood flow in patients is acting as another significant growth-inducing factor. Additionally, the rising demand for gene therapy, which involves introducing functional genetic material into cells to replace or rectify the genes responsible for high cholesterol, is also augmenting the market growth. Furthermore, the emerging popularity of regenerative medicines, since they hold the potential to repair and regenerate damaged blood vessels and cardiac tissue, is expected to drive the atherosclerotic cardiovascular disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the atherosclerotic cardiovascular disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for atherosclerotic cardiovascular disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the atherosclerotic cardiovascular disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the atherosclerotic cardiovascular disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the atherosclerotic cardiovascular disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current atherosclerotic cardiovascular disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the atherosclerotic cardiovascular disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the atherosclerotic cardiovascular disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the atherosclerotic cardiovascular disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of atherosclerotic cardiovascular disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of atherosclerotic cardiovascular disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of atherosclerotic cardiovascular disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with atherosclerotic cardiovascular disease across the seven major markets?
What is the size of the atherosclerotic cardiovascular disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of atherosclerotic cardiovascular disease?
What will be the growth rate of patients across the seven major markets?

Atherosclerotic Cardiovascular Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for atherosclerotic cardiovascular disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the atherosclerotic cardiovascular disease market?
What are the key regulatory events related to the atherosclerotic cardiovascular disease market?
What is the structure of clinical trial landscape by status related to the atherosclerotic cardiovascular disease market?
What is the structure of clinical trial landscape by phase related to the atherosclerotic cardiovascular disease market?
What is the structure of clinical trial landscape by route of administration related to the atherosclerotic cardiovascular disease market?